Bill Langbein

/Bill Langbein

Update on Eidos Therapeutics after Positive Phase II Results

Eidos Therapeutics, Inc. (NASDAQ:EIDX) shares are up as much as [...]

Galmed (GLMD) – November Catalyst: Aramchol

November Catalyst: Aramchol SanaCurrents forecasts an advantageous probability Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) [...]

Eidos Therapeutics (EIDX) – 4Q Catalyst: AG10 phase II data

4Q Catalyst: AG10 phase II data Based on its analytics [...]

FDA Creating New Investment Opportunities in BioTech Stocks

Because FDA marketing clearance to sell a drug or device [...]

SanaCurrents Introduction – Turn to the Biotech Experts to Maximize Your Returns

Introducing SanaCurrents It’s been 11 years since we launched GeoInvesting, [...]

ARMO Biosciences (ARMO) – SanaCurrents Case Study

ARMO Biosciences (ARMO) listed in January 2018 at $17 per [...]

Eiger Biopharmaceuticals (NASDAQ:EIGR) – SanaCurrents Case Study

Eiger Biopharmaceuticals (NASDAQ:EIGR), a company developing treatment for rare diseases, [...]

Top